Which Biomarkers Are Effective for Identifying Th2-Driven Inflammation in Asthma?

Zuzana Diamant*, Ellen Tufvesson, Leif Bjermer

*Corresponding author for this work

    Research output: Contribution to journalReview articleAcademicpeer-review

    10 Citations (Scopus)

    Abstract

    Recognition of asthma as a heterogeneous disease revealed different potential molecular targets and urged the development of targeted, customized treatment modalities. Evidence was provided for different inflammatory subsets of asthma and more recently, further refined to T helper (Th)2-high and Th2-low subphenotypes with different responsiveness to standard and targeted pharmacotherapy. Given these differences in immunology and pathophysiology, proof of concept studies of novel treatment modalities for asthma should be performed in adequate, well-defined phenotypes. In this review, we describe both existing and novel biomarkers of Th2-inflammation in asthma that can be applied to classify asthma subphenotypes in clinical studies and for treatment monitoring.

    Original languageEnglish
    Pages (from-to)477-486
    Number of pages10
    JournalCurrent Allergy and Asthma Reports
    Volume13
    Issue number5
    DOIs
    Publication statusPublished - Oct-2013

    Keywords

    • Asthma
    • Phenotype
    • Th2 inflammation
    • Biomarkers
    • Eosinophils
    • Periostin
    • TARC
    • Eotaxin
    • Feno
    • IL-4
    • IL-5
    • IL-13
    • Sputum
    • BAL
    • EOSINOPHIL CATIONIC PROTEIN
    • ACTIVATION-REGULATED CHEMOKINE
    • BRONCHOALVEOLAR LAVAGE FLUID
    • OBSTRUCTIVE PULMONARY-DISEASE
    • RANDOMIZED CONTROLLED-TRIAL
    • BRONCHIAL EPITHELIAL-CELLS
    • ASPIRIN-INTOLERANT ASTHMA
    • EXHALED BREATH CONDENSATE
    • NITRIC-OXIDE SYNTHASE
    • LATE-PHASE REACTIONS

    Cite this